Listed

NRX Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 16, 2022 and accepted by EDGAR at May 16, 2022, 16:08 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-01-01 to 2022-03-31$5.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$15.7mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-01-01 to 2022-03-31$3.0kus-gaap:InterestExpense
Income tax3 months2022-01-01 to 2022-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-01-01 to 2022-03-31−$13.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-01-01 to 2022-03-31−$0.20us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-01-01 to 2022-03-31−$0.21us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-01-01 to 2022-03-3163,667,468 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2022-01-01 to 2022-03-31−$10.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$3.0kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2022-03-31$40.2mus-gaap:Cash
Current assetsAt period end2022-03-31$43.6mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$43.6mus-gaap:Assets
Total liabilitiesAt period end2022-03-31$11.9mus-gaap:Liabilities
Shareholders' equityAt period end2022-03-31$31.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-22-008948. Last ingested by Listed: Nov 2, 2026, 08:07 ET. Listed shows no prices and gives no investment advice.